Tags

Type your tag names separated by a space and hit enter

Systemic effects of conjugated equine estrogen vaginal cream on bone turnover markers in postmenopausal women.
Climacteric. 2013 Feb; 16(1):133-40.C

Abstract

OBJECTIVE

To evaluate the systemic effect of therapy with conjugated equine estrogen (CEE) vaginal cream on bone turnover markers in postmenopausal women.

METHODS

This study was conducted in 40 spontaneously menopausal women aged 40-60 years who complained of vulvovaginal symptoms. Subjects were instructed to self-administer 1 g CEE vaginal cream (CEE 0.625 mg) once daily for 12 weeks (continuous phase), then twice weekly for the next 12 consecutive weeks (intermittent phase). Serum levels of bone turnover markers and estradiol and the vaginal maturation index were evaluated at baseline, 12 and 24 weeks after treatment initiation.

RESULTS

Levels of C-terminal cross-linked telopeptide of type I collagen (CTx) were significantly decreased at 12 weeks and 24 weeks when compared to baseline values (median (range) 0.435 (0.171-0.859) and 0.391 (0.122-0.714) vs. 0.562 (0.250-1.290) ng/ml (p < 0.001 and < 0.001), respectively), but there was no significant difference between the levels at 12 and 24 weeks. Levels of procollagen type I N-terminal propeptide (P1NP) and osteocalcin levels were significantly decreased after 24 weeks when compared to pretreatment levels (mean (standard deviation) 41.74 (11.76) vs. 50.02 (17.71) ng/ml (p = 0.002) for P1NP and 23.91 (7.11) vs. 27.54 (8.67) ng/ml (p < 0.001) for osteocalcin, respectively). Estradiol levels were significantly increased and the vaginal maturation index was significantly improved after 12 and 24 weeks when compared to baseline.

CONCLUSIONS

CEE vaginal cream significantly decreased the bone resorption marker (CTx) in postmenopausal women after completion of the continuous-treatment phase. There was no significant further decrease after the intermittent phase. The effects on the markers of bone formation and bone turnover (P1NP and osteocalcin) were apparent only at 24 weeks. The two treatment phases moderately increased serum estradiol levels and significantly improved the vaginal maturation index.

Authors+Show Affiliations

Menopause Research Unit, Reproductive Medicine Division, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22515801

Citation

Luengratsameerung, S, et al. "Systemic Effects of Conjugated Equine Estrogen Vaginal Cream On Bone Turnover Markers in Postmenopausal Women." Climacteric : the Journal of the International Menopause Society, vol. 16, no. 1, 2013, pp. 133-40.
Luengratsameerung S, Panyakhamlerd K, Treratanachat S, et al. Systemic effects of conjugated equine estrogen vaginal cream on bone turnover markers in postmenopausal women. Climacteric. 2013;16(1):133-40.
Luengratsameerung, S., Panyakhamlerd, K., Treratanachat, S., & Taechakraichana, N. (2013). Systemic effects of conjugated equine estrogen vaginal cream on bone turnover markers in postmenopausal women. Climacteric : the Journal of the International Menopause Society, 16(1), 133-40. https://doi.org/10.3109/13697137.2012.662252
Luengratsameerung S, et al. Systemic Effects of Conjugated Equine Estrogen Vaginal Cream On Bone Turnover Markers in Postmenopausal Women. Climacteric. 2013;16(1):133-40. PubMed PMID: 22515801.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Systemic effects of conjugated equine estrogen vaginal cream on bone turnover markers in postmenopausal women. AU - Luengratsameerung,S, AU - Panyakhamlerd,K, AU - Treratanachat,S, AU - Taechakraichana,N, Y1 - 2012/04/19/ PY - 2012/4/21/entrez PY - 2012/4/21/pubmed PY - 2013/7/6/medline SP - 133 EP - 40 JF - Climacteric : the journal of the International Menopause Society JO - Climacteric VL - 16 IS - 1 N2 - OBJECTIVE: To evaluate the systemic effect of therapy with conjugated equine estrogen (CEE) vaginal cream on bone turnover markers in postmenopausal women. METHODS: This study was conducted in 40 spontaneously menopausal women aged 40-60 years who complained of vulvovaginal symptoms. Subjects were instructed to self-administer 1 g CEE vaginal cream (CEE 0.625 mg) once daily for 12 weeks (continuous phase), then twice weekly for the next 12 consecutive weeks (intermittent phase). Serum levels of bone turnover markers and estradiol and the vaginal maturation index were evaluated at baseline, 12 and 24 weeks after treatment initiation. RESULTS: Levels of C-terminal cross-linked telopeptide of type I collagen (CTx) were significantly decreased at 12 weeks and 24 weeks when compared to baseline values (median (range) 0.435 (0.171-0.859) and 0.391 (0.122-0.714) vs. 0.562 (0.250-1.290) ng/ml (p < 0.001 and < 0.001), respectively), but there was no significant difference between the levels at 12 and 24 weeks. Levels of procollagen type I N-terminal propeptide (P1NP) and osteocalcin levels were significantly decreased after 24 weeks when compared to pretreatment levels (mean (standard deviation) 41.74 (11.76) vs. 50.02 (17.71) ng/ml (p = 0.002) for P1NP and 23.91 (7.11) vs. 27.54 (8.67) ng/ml (p < 0.001) for osteocalcin, respectively). Estradiol levels were significantly increased and the vaginal maturation index was significantly improved after 12 and 24 weeks when compared to baseline. CONCLUSIONS: CEE vaginal cream significantly decreased the bone resorption marker (CTx) in postmenopausal women after completion of the continuous-treatment phase. There was no significant further decrease after the intermittent phase. The effects on the markers of bone formation and bone turnover (P1NP and osteocalcin) were apparent only at 24 weeks. The two treatment phases moderately increased serum estradiol levels and significantly improved the vaginal maturation index. SN - 1473-0804 UR - https://www.unboundmedicine.com/medline/citation/22515801/Systemic_effects_of_conjugated_equine_estrogen_vaginal_cream_on_bone_turnover_markers_in_postmenopausal_women_ L2 - http://www.tandfonline.com/doi/full/10.3109/13697137.2012.662252 DB - PRIME DP - Unbound Medicine ER -